Complications of antifibrinolysis therapy after prostatectomy.
As part of a trial to compare the effectiveness of various agents which have been claimed to reduce blood loss after prostatectomy, tranexamic acid (AMCA) was given pre-operatively and post-operatively to 6 patients having routine transurethral resections. Three of these developed indissoluble intravesical blood clots which persisted until they were evacuated surgically 5 to 17 days after cessation of AMCA therapy. AMCA cannot be recommended for routine use after prostatectomy.
D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy*; D011468:Prostatectomy / Q000009:adverse effects*; D014148:Tranexamic Acid / Q000627:therapeutic use*; D001743:Urinary Bladder / Q000601:surgery
D003509:Cyclohexanecarboxylic Acids; D014148:Tranexamic Acid